Resection of oesophageal and oesophagogastric junction cancer liver metastases — a summary of current evidence
-
Published:2021-12-03
Issue:
Volume:
Page:
-
ISSN:1435-2443
-
Container-title:Langenbeck's Archives of Surgery
-
language:en
-
Short-container-title:Langenbecks Arch Surg
Author:
Weiss Andreas R. R.ORCID, Donlon Noel E., Schlitt Hans J., Hackl Christina
Abstract
Abstract
Purpose
Metastatic oesophageal cancer is commonly considered as a palliative situation with a poor prognosis. However, there is increasing evidence that well-selected patients with a limited number of liver metastases (ECLM) may benefit from a multimodal approach including surgery.
Methods
A systematic review of the current literature for randomized trials, retrospective studies, and case series with patients undergoing hepatectomies for oesophageal and oesophagogastric junction cancer liver metastases was conducted up to the 31st of August 2021 using the MEDLINE (PubMed) and Cochrane Library databases.
Results
A total of 661 articles were identified. After removal of duplicates, 483 articles were screened, of which 11 met the inclusion criteria. The available literature suggests that ECLM resection in patients with liver oligometastatic disease may lead to improved survival and even long-term survival in some cases. The response to concomitant chemotherapy and liver resection seems to be of significance. Furthermore, a long disease-free interval in metachronous disease, low number of liver metastases, young age, and good overall performance status have been described as potential predictive markers of outcome for the resection of liver metastases.
Conclusion
Surgery may be offered to carefully selected patients to potentially improve survival rates compared to palliative treatment approaches. Studies with standardized patient selection criteria and treatment protocols are required to further define the role for surgery in ECLM. In this context, particular consideration should be given to neoadjuvant treatment concepts including immunotherapies in stage IVB oesophageal and oesophagogastric junction cancer.
Funder
Universitätsklinikum Regensburg
Publisher
Springer Science and Business Media LLC
Reference44 articles.
1. Van Hagen P, Hulshof MC, van Lanschot JJ, Steyerberg EW, van Berge Henegouwen MI, Wijnhoven BP, Richel DJ, Nieuwenhuijzen GA, Hospers GA, Bonenkamp JJ, Cuesta MA, Blaisse RJ, Busch OR, ten Kate FJ, Creemers GJ, Punt CJ, Plukker JT, Verheul HM, SpillenaarBilgen EJ, van Dekken H, van der Sangen MJ, Rozema T, Biermann K, Beukema JC, Piet AH, van Rij CM, Reinders JG, Tilanus HW, van der Gaast A, CROSS Group (2012) Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med 366:2074–2084. https://doi.org/10.1056/NEJMoa1112088 (PMID: 22646630) 2. Donlon NE, Ravi N, King S, Cunninhgam M, Cuffe S, Lowery M, Wall C, Hughes N, Muldoon C, Ryan C, Moore J, O’Farrell C, Gorry C, Duff AM, Enright C, Nugent TS, Elliot JA, Donohoe CL, Reynolds JV (2021) Modern oncological and operative outcomes in oesophageal cancer: the St. James’s hospital experience. Ir J Med Sci 190:297–305. https://doi.org/10.1007/s11845-020-02321-4 (PMID: 32696244) 3. Janmaat VT, Steyerberg EW, van der Gaast A, Mathijssen RH, Bruno MJ, Peppelenbosch MP, Kuipers EJ, Spaander MC (2017) Palliative chemotherapy and targeted therapies for esophageal and gastroesophageal junction cancer. Cochrane Database Syst Rev 11:004063. https://doi.org/10.1002/14651858.CD004063.pub4 (PMID: 29182797) 4. Procopio F, Marano S, Gentile D, Da Roit A, Basato S, Riva P, De Vita F, Torzilli G, Castoro C (2019) Management of liver oligometastatic esophageal cancer: overview and critical analysis of the different loco-regional treatments. Cancers (Basel) 12:20. https://doi.org/10.3390/cancers12010020 (PMID: 31861604) 5. Seesing MFJ, van der Veen A, Brenkman HJF, Stockmann HBAC, Nieuwenhuijzen GAP, Rosman C, van den Wildenberg FJH, van Berge Henegouwen MI, van Duijvendijk P, Wijnhoven BPL, Stoot JHMB, Lacle M, Ruurda JP, van Hillegersberg R, Gastroesophageal Metastasectomy Group (2019) Resection of hepatic and pulmonary metastasis from metastatic esophageal and gastric cancer: a nationwide study. Dis Esophagus 32:doz034. https://doi.org/10.1093/dote/doz034 (PMID: 31220859)
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|